The U.S. Food and Drug Administration (FDA) has approved atezolizumab (Tecentriq) and atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza) for certain patients with muscle-invasive bladder cancer (MIBC) after bladder removal surgery (cystectomy). The FDA also approved Signatera CDx as the companion diagnostic test used to identify eligible patients. This approval marks an important step toward more personalized […]

A new real-world study is raising important questions about whether some patients with advanced bladder cancer may benefit from adding local treatment, such as surgery or radiation, after responding to systemic therapy with enfortumab vedotin (EV) and pembrolizumab (pembro). While the findings are early and not yet practice-changing, they highlight a growing area of interest […]

Discover how precision nutrition supports your body during cancer treatment. Learn meal ideas, appetite tips, and which foods to avoid for better recovery.